BACKGROUND: Extracellular microRNAs (miRNAs) have been proposed as potentially robust and stable biomarkers of various disease conditions. The primary objective of this study was to identify miRNAs differentially occurring in the urine that could serve as potential biomarkers of acute kidney injury (AKI), because traditional AKI markers have limitations with respect to sensitivity, specificity, and timeliness of diagnosis. METHODS: We profiled 1809 miRNAs in pooled urine samples from 6 patients with AKI and from 6 healthy controls. We measured the 378 stably detectable miRNAs in the 12 samples individually and selected the top 7 miRNAs that were most different in the urine of patients with AKI compared with the non-AKI control individuals. These miRNAs were assessed in a larger cohort of patients with AKI (n = 98: 71 AKI patients in the intensive care unit (ICU) and 27 kidney transplantation patients with biopsy-proven tubular injury) and patients without AKI (n = 97: 74 healthy volunteers and 23 ICU patients without AKI). RESULTS: We identified 4 miRNAs capable of significantly differentiating patients with AKI from individuals without AKI: miR-21 (P = 0.0005), miR-200c (P < 0.0001), miR-423 (P = 0.001), and miR-4640 (P = 0.0355). The combined cross-validated area under the ROC curve for these 4 miRNAs was 0.91. The imprecision with respect to miRNA isolation and reverse transcription efficiency was <9% across 224 samples. CONCLUSIONS: In this study we determined the entire miRNome of human urine and identified a panel of miRNAs that are both detectable noninvasively and diagnostically sensitive indicators of kidney damage.
BACKGROUND: Extracellular microRNAs (miRNAs) have been proposed as potentially robust and stable biomarkers of various disease conditions. The primary objective of this study was to identify miRNAs differentially occurring in the urine that could serve as potential biomarkers of acute kidney injury (AKI), because traditional AKI markers have limitations with respect to sensitivity, specificity, and timeliness of diagnosis. METHODS: We profiled 1809 miRNAs in pooled urine samples from 6 patients with AKI and from 6 healthy controls. We measured the 378 stably detectable miRNAs in the 12 samples individually and selected the top 7 miRNAs that were most different in the urine of patients with AKI compared with the non-AKI control individuals. These miRNAs were assessed in a larger cohort of patients with AKI (n = 98: 71 AKI patients in the intensive care unit (ICU) and 27 kidney transplantation patients with biopsy-proven tubular injury) and patients without AKI (n = 97: 74 healthy volunteers and 23 ICU patients without AKI). RESULTS: We identified 4 miRNAs capable of significantly differentiating patients with AKI from individuals without AKI: miR-21 (P = 0.0005), miR-200c (P < 0.0001), miR-423 (P = 0.001), and miR-4640 (P = 0.0355). The combined cross-validated area under the ROC curve for these 4 miRNAs was 0.91. The imprecision with respect to miRNA isolation and reverse transcription efficiency was <9% across 224 samples. CONCLUSIONS: In this study we determined the entire miRNome of human urine and identified a panel of miRNAs that are both detectable noninvasively and diagnostically sensitive indicators of kidney damage.
Authors: Vishal S Vaidya; Sushrut S Waikar; Michael A Ferguson; Fitz B Collings; Kelsey Sunderland; Costas Gioules; Gary Bradwin; Roland Matsouaka; Rebecca A Betensky; Gary C Curhan; Joseph V Bonventre Journal: Clin Transl Sci Date: 2008-12 Impact factor: 4.689
Authors: Johan M Lorenzen; Jan T Kielstein; Carsten Hafer; Shashi K Gupta; Philipp Kümpers; Robert Faulhaber-Walter; Hermann Haller; Danilo Fliser; Thomas Thum Journal: Clin J Am Soc Nephrol Date: 2011-06-23 Impact factor: 8.237
Authors: Raymond K Hsu; Charles E McCulloch; R Adams Dudley; Lowell J Lo; Chi-yuan Hsu Journal: J Am Soc Nephrol Date: 2012-12-06 Impact factor: 10.121
Authors: Jeannie L Te; Igor M Dozmorov; Joel M Guthridge; Kim L Nguyen; Joshua W Cavett; Jennifer A Kelly; Gail R Bruner; John B Harley; Joshua O Ojwang Journal: PLoS One Date: 2010-05-11 Impact factor: 3.240
Authors: Vishal S Vaidya; Josef S Ozer; Frank Dieterle; Fitz B Collings; Victoria Ramirez; Sean Troth; Nagaraja Muniappa; Douglas Thudium; David Gerhold; Daniel J Holder; Norma A Bobadilla; Estelle Marrer; Elias Perentes; André Cordier; Jacky Vonderscher; Gérard Maurer; Peter L Goering; Frank D Sistare; Joseph V Bonventre Journal: Nat Biotechnol Date: 2010-05 Impact factor: 54.908
Authors: Sameer R Oak; Lynne Murray; Athula Herath; Matthew Sleeman; Ian Anderson; Amrita D Joshi; Ana Lucia Coelho; Kevin R Flaherty; Galen B Toews; Darryl Knight; Fernando J Martinez; Cory M Hogaboam Journal: PLoS One Date: 2011-06-21 Impact factor: 3.240
Authors: M Cárdenas-González; C Osorio-Yáñez; O Gaspar-Ramírez; M Pavković; A Ochoa-Martínez; D López-Ventura; M Medeiros; O C Barbier; I N Pérez-Maldonado; V S Sabbisetti; J V Bonventre; V S Vaidya Journal: Environ Res Date: 2016-07-15 Impact factor: 6.498
Authors: Kristien J Ledeganck; Els M Gielis; Daniel Abramowicz; Peter Stenvinkel; Paul G Shiels; Amaryllis H Van Craenenbroeck Journal: Clin J Am Soc Nephrol Date: 2019-01-02 Impact factor: 8.237
Authors: Mariana Cardenas-Gonzalez; Anand Srivastava; Mira Pavkovic; Vanesa Bijol; Helmut G Rennke; Isaac E Stillman; Xiaolan Zhang; Samir Parikh; Brad H Rovin; Maryam Afkarian; Ian H de Boer; Jonathan Himmelfarb; Sushrut S Waikar; Vishal S Vaidya Journal: Clin Chem Date: 2017-06-30 Impact factor: 8.327
Authors: Robert N Jamison; Marc O Martel; Robert R Edwards; Jing Qian; Kerry Anne Sheehan; Edgar L Ross Journal: J Pain Date: 2014-08-01 Impact factor: 5.820